The antibiotic susceptibility of methicillin-resistant Staphylococcus aureus
Abstract number: 1134_02_213
Gavriliu L., Popescu G.A., Benea E., Popescu C., Badea G., Ivan M., Popoiu M., Botea S.
Methicillin-resistant staphylococci (MRSA) are often multidrug resistant and represent a major problem for the antimicrobial therapy. Glicopeptides are the golden standard for these infections but resistance and toxicity concerns limit their usage. MRSA antibiotic resistance may be divided into two distinctive profiles: multidrug resistance (probably nosocomial infections) and variable resistance, usually to 1 or 2 non-betalactamic antibiotics (often correlated with community-related MRSA infections).
To characterize the susceptibility of MRSA to non-betalactamic antibiotics, in order to evaluate the therapeutical alternatives when a MRSA infection is suspected.
A retrospective study of 65 MRSA strains isolated and drug-susceptibility tested in Matei Bals Institute of Infectious Diseases in 2003.
The most active of all the tested antibiotics proved to be linezolid (100%), vancomycin (95.48%) and clindamycin (77.58%) and less active were tetracycline (16.08%) , cloramphenycol (33.3%), rifampin (45.65%) and fluorquinolones (42.3%).25 MRSA isolated strains (38.46%) were sensible to less than 4 antibiotics; the most active have been linezolid (100%) and vancomycin (95.48% - two VISA strains).For the 40 MRSA more sensible strains, the efficiency was similar for linezolid, vancomycin (1 strain VISA), clindamycin (90%) and trimethoprim/sulfamethoxazole (77.56%).
The therapeutic alternatives are linezolid and glicopeptides, for nosocomial or health-related infections, TMP/SMX and clindamycin, for community-acquirred infections. The decision to use one of these should be correlated to the clinical findings.
|Session name:||XXIst ISTH Congress|
|Back to top|